PBM
STRO icon

Propel Bio Management’s Sutro Biopharma STRO Stock Holding History

Propel Bio Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,500
Closed -$1.1M – 30
2024
Q1 		$1.1M Hold
19,500
– – 0.64% 21
2023
Q4 		$837K Buy
+19,500
New +$619K 0.69% 26

Other funds holding STRO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Propel Bio Management's STRO Position: Q2 2024 in Review

Propel Bio Management sold out of Sutro Biopharma (STRO) in Q2 2024, closing a stake of 19,500 shares — an estimated $1.1M sold.

Propel Bio Management first reported a position in STRO in Q4 2023 and held it in 2 quarters. The position peaked at $1.1M in Q1 2024. 119 funds tracked by Wall St. Rank hold STRO as of Q2 2024.

  • Propel Bio Management reported no remaining Sutro Biopharma position as of Q2 2024 after selling out during the quarter.
  • Propel Bio Management sold 19,500 Sutro Biopharma shares in Q2 2024, an estimated $1.1M.
  • Propel Bio Management first reported a position in Sutro Biopharma in Q4 2023 and held it in 2 quarters.
  • Propel Bio Management's Sutro Biopharma position peaked at $1.1M in Q1 2024.
  • 119 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2024.

Based on Propel Bio Management's 13F filing for Q2 2024, filed 12 Aug 2024.